Bibliography
- Vanhaesebroeck B, Waterfield MD. Signaling by distinct classes of phosphoinositide 3-kinases. Exp Cell Res 1999;253(1):239-54
- Holmes D. PI3K pathway inhibitors approach junction. Nat Rev Drug Discov 2011;10(8):563-4
- Liu P, Cheng H, Roberts TM, Zhao JJ. Targeting the phosphoinositide 3-kinase pathway in cancer. Nat Rev Drug Discov 2009;8(8):627-44
- Huang CH, Mandelker D, Gabelli SB, Amzel LM. Insights into the oncogenic effects of PIK3CA mutations from the structure of p110alpha/p85alpha. Cell Cycle 2008;7(9):1151-6
- Vanhaesebroeck B, Welham MJ, Kotani K, P110delta, a novel phosphoinositide 3-kinase in leukocytes. Proc Natl Acad Sci USA 1997;94(9):4330-5
- Norman P. Selective PI3Kdelta inhibitors, a review of the patent literature. Expert Opin Ther Patent 2011;21(11):1773-90
- Fruman DA, Rommel C. PI3Kdelta inhibitors in cancer: rationale and serendipity merge in the clinic. Cancer Discov 2011;1(7):562-72
- Castillo JJ, Furman M, Winer ES. CAL-101: a phosphatidylinositol-3-kinase p110-delta inhibitor for the treatment of lymphoid malignancies. Expert Opin Investig Drugs 2012;21(1):15-22
- Mattheakis L, Kearney P, Jaeger C, PI3Kdelta: discovery of potent and selective inhibitors for treating hematopoietic malignancies. 22nd EORTC-NCI-AACR symposium on “Molecular targets and Cancer Therapeutics” 2010. p. P219
- Exelixis, Inc. Inhibitors of PI3K-Delta and methods of their use and manufacture. WO2012037204; 2012
- Exelixis, Inc. Inhibitors of PI3K-delta and methods of their use and manufacture. WO2012037226; 2012
- Leahy JW, Buhr CA, Johnson HW, Discovery of a novel series of potent and orally bioavailable phosphoinositide 3-Kinase delta inhibitors. J Med Chem 2012. DOI: 10.1021/jm300403a
- UCB Pharma SA. Quinoline and quinoxaline derivatives as kinase inhibitors. WO2011058108; 2011
- Exelixis Inc. “Exelixis Licenses PI3K-Delta Program to Merck” press release 21; 2011
- Norman P. Two selective PI3Kdelta inhibitors, which is GSK-2269557? Expert Opin Ther Patent. 2012;22:( preceding paper)